The CleanFuze implants include DiFusion’s biomaterial technology to resist infection and form a direct and lasting connection with bone. The material uses metallic ions as therapeutic agents to effect cellular signaling as well as upstream and downstream cellular metabolic processes.
The company will launch its CleanFuze Xiphos spinal implant in the European Union later this year.
More Articles on Orthopedic and Spine Devices:
Symmetry Medical Reports Flat 2Q Revenue, Net Income Down 30%
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA 510(k) Clearance for Titan Reverse Shoulder System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
